For research use only. Not for therapeutic Use.
ONC206 is an analogue of TRAIL inducer ONC201[1]. ONC206 is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 has broad-spectrum anti-tumor activity[2].
ONC206 selectively antagonizes the D2-like (DRD2/3/4), but not the D1-like (DRD 1/5), subfamily of dopamine receptors[2].?
ONC206 significantly inhibits tumor cell migration and invasion in vitro[1].?
ONC206 (0.05 μM; Over 48 hours) inhibits migration of ONC201- and TRAIL-resistant HCT116 Bax?/? cells without inducing cell death or inhibiting cell proliferation[1].?
ONC206 engages the ISR and TRAIL pathway leading to tumor growth arrest and cell death[1].?
ONC206 does not induce cell cycle arrest in a colorectal cell line with acquired ONC201-resistance[1].
ONC206 (100 mg/kg;p.o.; every 10 days) causes significant tumor growth inhibition[2].
| Catalog Number | I017529 |
| CAS Number | 1638178-87-6 |
| Synonyms | 11-benzyl-7-[(2,4-difluorophenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one |
| Molecular Formula | C23H22F2N4O |
| Purity | ≥95% |
| InChI | InChI=1S/C23H22F2N4O/c24-18-7-6-17(20(25)12-18)14-29-22(30)19-15-27(13-16-4-2-1-3-5-16)10-8-21(19)28-11-9-26-23(28)29/h1-7,12H,8-11,13-15H2 |
| InChIKey | ITMGVSSHWMTJRR-UHFFFAOYSA-N |
| SMILES | C1CN(CC2=C1N3CCN=C3N(C2=O)CC4=C(C=C(C=C4)F)F)CC5=CC=CC=C5 |
| Reference | [1]. Wagner J, et al. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. [2]. Varun Vijay Prabhu, et al. Potent anti-cancer activity of the imipridone ONC206: A selective dopamine D2-like receptor antagonist. AACR Annual Meeting 2017, April 1-5, 2017; Washington, DC. |
